Please select the option that best describes you:
Topics:
Radiation Oncology • Genitourinary Cancers • Prostate Cancer • Medical Oncology • Nuclear Medicine • ASTRO 2026
Do you modify dosing and monitoring of Lu-177–PSMA therapy for patients with prior large-field RT involving substantial active marrow compared with patients who only had focal bone SBRT?
This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This question is inspired by the Plenary Session Presentation "Hematologic Toxicity Outcomes of Lu-PSMA-617 in Patients Previously Treated with EBRT for Oligometastatic Disease" by Dr. Daniel B. Rosen
Answer from: Radiation Oncologist at Academic Institution
No, we do not modify dosing and monitoring of PSMA therapy with prior large-field RT. In the VISION trial, the vast majority of patients were heavily pre-treated, presumably many with pelvic radiation for definitive treatment or treatment for bCR prior to metastasis. Assuming that the patient had ap...
Sign In or Register to read more